Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE. Praiss AM, et al. Gynecol Oncol. 2023 Jul;174:213-223. doi: 10.1016/j.ygyno.2023.05.013. Epub 2023 May 23. Gynecol Oncol. 2023. PMID: 37229879 Clinical Trial.
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
Ehmann S, Sassine D, Straubhar AM, Praiss AM, Aghajanian C, Alektiar KM, Broach V, Cadoo KA, Jewell EL, Boroujeni AM, Kyi C, Leitao MM, Mueller JJ, Murali R, Bhaloo SI, O'Cearbhaill RE, Park KJ, Sonoda Y, Weigelt B, Zamarin D, Abu-Rustum N, Friedman CF. Ehmann S, et al. Among authors: praiss am. Gynecol Oncol. 2022 Dec;167(3):458-466. doi: 10.1016/j.ygyno.2022.10.003. Epub 2022 Oct 15. Gynecol Oncol. 2022. PMID: 36253302 Free PMC article.
Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial.
Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, Chi DS, O'Cearbhaill RE, Zivanovic O. Praiss AM, et al. Gynecol Oncol. 2023 Apr;171:23-30. doi: 10.1016/j.ygyno.2023.02.003. Epub 2023 Feb 16. Gynecol Oncol. 2023. PMID: 36804618 Free PMC article. Clinical Trial.
Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Sia TY, Manning-Geist BL, Ehmann S, Lavery JA, Luardo C, Praiss A, Iasonos A, Sonoda Y, Grisham RN, Liu YL, Broach V, Zivanovic O, Long Roche K, Gardner GJ, Chi DS. Sia TY, et al. Gynecol Oncol. 2023 Sep;176:69-75. doi: 10.1016/j.ygyno.2023.07.006. Epub 2023 Jul 14. Gynecol Oncol. 2023. PMID: 37454565
TERT promoter mutations and gene amplification in endometrial cancer.
Praiss AM, Marra A, Zhou Q, Rios-Doria E, Momeni-Boroujeni A, Iasonos A, Selenica P, Brown DN, Aghajanian C, Abu-Rustum NR, Ellenson LH, Weigelt B. Praiss AM, et al. Gynecol Oncol. 2023 Dec;179:16-23. doi: 10.1016/j.ygyno.2023.10.007. Epub 2023 Oct 25. Gynecol Oncol. 2023. PMID: 37890416
21 results